Treating side effects of atypical antipsychotics
Ligand-bound gold clusters address the inefficacies of existing treatments for antipsychotic side effects by reducing weight gain and metabolic disorders in a dose-dependent manner.
Patent Information
- Application Number
- JP2022567028
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-05-09
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2040-05-09
AI Technical Summary
Current strategies to counteract side effects of second-generation antipsychotics like olanzapine and clozapine, such as weight gain and metabolic abnormalities, are inconclusive or contradictory, and the underlying mechanisms remain unclear.
Development of pharmaceutical compositions containing ligand-bound gold clusters (AuCs) with diameters between 0.5 and 3 nm, using ligands such as L-cysteine and its derivatives, to treat side effects caused by atypical antipsychotics.
The compositions effectively reduce weight gain, fat accumulation, and improve glucose metabolism disorders induced by olanzapine, demonstrating a dose-dependent efficacy in animal models.
Smart Images

Figure 0007595087000006 
Figure 0007595087000007 
Figure 0007595087000008
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of antipsychotics, and in particular to ligand-conjugated gold clusters (AuCs), compositions comprising ligand-conjugated AuCs, and methods employing the ligand-conjugated AuCs and compositions to prevent, inhibit, reduce and / or reverse side effects caused by atypical antipsychotics. [Background technology]
[0002] Atypical antipsychotics are second-generation antipsychotics currently used to treat a variety of psychiatric conditions, including schizophrenia, bipolar disorder, depression, and autism. Antipsychotics, although documented in the literature for their high therapeutic efficacy and low risk of extrapyramidal symptoms, can generally lead to a variety of side effects, including obesity, characterized by excessive weight gain, lipid metabolism disorders, and glucose metabolism disorders. For example, subjects taking olanzapine or clozapine are at highest risk of experiencing weight gain. The rapid progression of weight gain suggests a unique etiology behind atypical antipsychotic-induced metabolic syndrome.
[0003] Unfortunately, the mechanisms underlying various side effects, such as weight gain and metabolic abnormalities, caused by second-generation atypical antipsychotics remain largely unknown, despite extensive research to date.
[0004] Olanzapine has high binding affinity with multiple neurotransmitter receptors, including dopamine D2, serotonin 5-HT2A and 5-HT2C, histamine H1 receptors, and muscarinic M1 and M3 receptors. Many pharmacological adjunctive treatments have been attempted to counteract olanzapine-induced weight gain. For example, co-treatment of olanzapine with betahistine (an H1R agonist and H3R antagonist) significantly reduces olanzapine-induced weight gain (Lian et al. Preventing Olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One. 2014, 9(8): e104160). Other examples include telenzepine, a muscarinic acetylcholine receptor M1 subtype antagonist for the treatment of olanzapine-induced weight gain (WO2011 / 011238A1), pramipexole, a dopamine agonist for preventing or reducing weight gain and associated metabolic syndrome in subjects receiving atypical antipsychotics, including clozapine, olanzapine, quetiapine and risperidone (WO 2009 / 059418A1), and histamine H2 receptor antagonists selected from the group consisting of nizatidine, famotidine, cimitidine and lenitidine.However, the results of these agonists or antagonists are inconclusive or contradictory.
[0005] Better strategies are needed to counter the side effects of second-generation antipsychotics such as olanzapine and clozapine. Summary of the Invention
[0006] The present invention relates to including ligand-bound gold clusters, To treat side effects caused by atypical antipsychotics Pharmaceutical Compositions to provide.
[0007] Certain embodiments of the present invention provide a method for treating side effects of atypical antipsychotics. A pharmaceutical composition, comprising:Ligand-bound gold clusters Includes the ligand-bound gold cluster comprises a gold core and a ligand bound to the gold core; Pharmaceutical compositions are provided In certain embodiments, the atypical antipsychotic is a member selected from the group consisting of olanzapine, clozapine, risperidone, and quetiapine.
[0008] The above Pharmaceutical Compositions In certain embodiments, the gold core has a diameter of 0.5 to 3 nm, In certain embodiments, the gold core has a diameter of 0.5 to 2.6 nm.
[0009] In certain embodiments of the pharmaceutical composition, the ligand is a member selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds.
[0010] The above Pharmaceutical Compositions In certain embodiments, the L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC), and N-acetyl-L-cysteine (L-NAC), and the D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC), and N-acetyl-D-cysteine (D-NAC).
[0011] The above Pharmaceutical Compositions In certain embodiments, said cysteine-containing oligopeptides and their derivatives are cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides.
[0012] The above Pharmaceutical CompositionsIn certain embodiments, the cysteine-containing dipeptide is selected from the group consisting of L(D)-cysteine-L(D)-arginine dipeptide (CR), L(D)-arginine-L(D)-cysteine dipeptide (RC), L(D)-histidine-L(D)-cysteine dipeptide (HC), and L(D)-cysteine-L(D)-histidine dipeptide (CH).
[0013] The above Pharmaceutical Compositions In certain embodiments, the cysteine-containing tripeptide is selected from the group consisting of glycine-L(D)-cysteine-L(D)-arginine tripeptide (GCR), L(D)-proline-L(D)-cysteine-L(D)-arginine tripeptide (PCR), L(D)-lysine-L(D)-cysteine-L(D)-proline tripeptide (KCP), and L(D)-glutathione (GSH).
[0014] The above Pharmaceutical Compositions In certain embodiments, the cysteine-containing tetrapeptide is selected from the group consisting of glycine-L(D)-serine-L(D)-cysteine-L(D)-arginine tetrapeptide (GSCR) and glycine-L(D)-cysteine-L(D)-serine-L(D)-arginine tetrapeptide (GCSR).
[0015] The above Pharmaceutical Compositions In certain embodiments, the other thiol-containing compound is selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-penicillamine, N-(2-mercaptopropionyl)-glycine, dodecyl mercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA), and 4-mercaptobenzoic acid (p-MBA).
[0016] The objects and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment thereof when taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0017] Hereinafter, preferred embodiments of the present invention will be described with reference to the drawings.
[0018] [Figure 1] Figure 1 shows ultraviolet-visible (UV) spectra, transmission electron microscope (TEM) images, and particle size distribution diagrams of gold nanoparticles modified with the ligand L-NIBC (L-NIBC-AuNPs) of various particle sizes.
[0019] [Diagram 2] Figure 1 shows ultraviolet-visible (UV) spectra, TEM images, and particle size distribution diagrams of ligand L-NIBC-conjugated gold clusters (L-NIBC-AuCs) of various particle sizes.
[0020] [Diagram 3] 1 shows infrared spectra of L-NIBC-AuCs with various particle sizes.
[0021] [Figure 4] The UV spectrum, infrared, TEM images, and particle size distribution diagram of the ligand CR-conjugated gold clusters (CR-AuCs) are shown.
[0022] [Diagram 5] The UV spectrum, infrared spectrum, TEM image, and particle size distribution map of the ligand RC-conjugated gold clusters (RC-AuCs) are shown.
[0023] [Figure 6] The UV spectrum, infrared spectrum, TEM image, and particle size distribution diagram of the ligand 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline (i.e., Cap)-bound gold clusters (Cap-AuCs) are shown.
[0024] [Figure 7] The UV spectrum, infrared spectrum, TEM image, and particle size distribution map of the ligand GSH-conjugated gold clusters (GSH-AuCs) are shown.
[0025] [Figure 8] The UV spectrum, infrared spectrum, TEM image, and particle size distribution diagram of the ligand D-NIBC-conjugated gold clusters (D-NIBC-AuCs) are shown.
[0026] [Figure 9] The UV spectrum, infrared spectrum, TEM image, and particle size distribution diagram of the ligand L-cysteine-conjugated gold cluster (L-Cys-AuC) are shown.
[0027] [Figure 10] The UV spectrum, infrared spectrum, TEM image, and particle size distribution map of the ligand 2-aminoethanethiol-conjugated gold clusters (CSH-AuCs) are shown.
[0028] [Figure 11] The UV spectrum, infrared spectrum, TEM image, and particle size distribution diagram of the ligand 3-mercaptopropionic acid-bound gold clusters (MPA-AuCs) are shown.
[0029] [Figure 12] The UV spectrum, infrared spectrum, TEM image, and particle size distribution diagram of the ligand 4-mercaptobenzoic acid-bound gold clusters (p-MBA-AuCs) are shown.
[0030] [Figure 13] (A) Blood glucose metabolism curve and (B) area under the blood glucose curve (AUG) in each group of rats are shown. CON: negative control group; OLZ: olanzapine model control group; OLZ+A1H: OLZ+A1 high dose group; OLZ+A1L: OLZ+A1 low dose group; OLZ+A2H: OLZ+A2 high dose group; OLZ+A2L: OLZ+A2 low dose group; OLZ+A3H: OLZ+A3 high dose group; OLZ+A3L: OLZ+A3 low dose group; OLZ+B: OLA+B high dose group; *: P<0.05; **: P<0.01. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] The present invention may be understood more readily by reference to the following detailed description of specific embodiments of the invention.
[0032] Throughout this application, publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention applies.
[0033] As used herein, "administering" means administering orally ("po"), as a suppository, topical contact, intravenous ("iv"), intraperitoneal ("ip"), intramuscular ("im"), intraluminal, intranasal or subcutaneous ("sc") administration, or implantation of a sustained release device (e.g., a mini-osmotic pump or an erodible implant) into a subject. Administration is by any route, including parenteral and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like.
[0034] The terms "systemic administration" and "administered systemically" refer to a method of administering a compound or composition to a mammal such that the compound or composition is delivered via the circulatory system to a site within the body, including the target site of pharmaceutical action. Systemic administration includes, but is not limited to, oral, intranasal, rectal and parenteral (i.e., administration outside the digestive tract, such as intramuscular, intravenous, intraarterial, transdermal and subcutaneous), but does not include administration directly to brain regions by means other than the circulatory system, such as intrathecal injection and intracranial administration.
[0035] As used herein, the terms "treat" and "treatment" refer to delaying the onset of, delaying or reversing the course of, or alleviating or preventing one or more symptoms of, the disease or condition to which the term applies. An exemplary indicator herein is the rate of weight gain. Depending on the patient, treatment can reduce weight gain, e.g., by 5%, 10%, 15%, 20%, 25% or more, compared to the weight gain experienced by the same or different patient without treatment or the average weight gain of a population of patients receiving antipsychotics for the same or similar time period. In some patients, the treatment can result in a reversal of antipsychotic-induced weight gain, i.e., weight loss. For example, some patients receiving treatment can lose, e.g., 5%, 10%, 15%, 20%, 25%, 50%, 75%, or 100% of antipsychotic weight gain, e.g., return to the weight maintained before administering antipsychotics without treatment.
[0036] The terms "patient," "subject," or "individual" mean a mammal, e.g., a human or a non-human mammal, including primates (e.g., macaques, Pan troglodytes, pongos), domesticated mammals (e.g., felines, canines), agricultural mammals (e.g., bovines, ovines, porcines, equines), and laboratory mammals or rodents (e.g., rats, mice, rabbits, hamsters, guinea pigs).
[0037] The term "atypical antipsychotic side effects" refers to any of the known side effects including obesity, characterized by obese weight gain, lipid and glucose metabolism disorders. The term "antipsychotic-induced weight gain" refers to the side effect of weight gain experienced by patients receiving atypical antipsychotic medication. Atypical antipsychotics include olanzapine, clozapine, risperidone, and quetiapine.
[0038] Both olanzapine and clozapine are characterized as nonselective acetylcholine muscarinic receptor (Ach-M) antagonists.
[0039] The chemical name of olanzapine is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine. Its molecular formula is C 17 H 20 It is N4S, which corresponds to a molecular weight of 312.44. Olanzapine is classified as a thienobenzodiazepine. Its chemical structure is: JPEG0007595087000001.jpg2926
[0040] The chemical name of clozapine is 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)azepine. Its molecular formula is C 18 H 19 It has a molecular weight of 326.8 and its chemical structure is: JPEG0007595087000002.jpg3435
[0041] Gold clusters (AuCs) are a special form of gold that exists between gold atoms and gold nanoparticles. AuCs are less than 3 nm in size and consist of a few to hundreds of gold atoms, which disrupts the face-centered cubic stacking structure of gold nanoparticles. As a result, AuCs exhibit a molecular-like discretized electronic structure with a different HOMO-LUMO gap, unlike the continuous or quasi-continuous energy levels of gold nanoparticles. This causes the disappearance of the surface plasmon resonance effect and the corresponding plasmon resonance absorption band (520 ± 20 nm) in the uv-vis spectrum of conventional gold nanoparticles.
[0042] The present invention provides ligand-conjugated AuC.
[0043] In certain embodiments, the ligand-bound AuC comprises a ligand and a gold core, the ligand being bound to the gold core. Binding a ligand to a gold core means that the ligand forms a complex with the gold core that is stable in solution via covalent bonds, hydrogen bonds, electrostatic forces, hydrophobic forces, van der Waals forces, etc. In certain embodiments, the diameter of the gold core is in the range of 0.5-3 nm. In certain embodiments, the diameter of the gold core is in the range of 0.5-2.6 nm.
[0044] In certain embodiments, the ligand of the ligand-conjugated AuC is a thiol-containing compound or an oligopeptide, hi certain embodiments, the ligand is bound to a gold core via an Au-S bond to form the ligand-conjugated AuC.
[0045] In certain embodiments, the ligand is, but not limited to, L-cysteine, D-cysteine, or a cysteine derivative.In certain embodiments, the cysteine derivative is N-isobutyryl-L-cysteine (L-NIBC), N-isobutyryl-D-cysteine (D-NIBC), N-acetyl-L-cysteine (L-NAC), or N-acetyl-D-cysteine (D-NAC).
[0046] In certain embodiments, the ligand is, but is not limited to, a cysteine-containing oligopeptide and its derivatives. In certain embodiments, the cysteine-containing oligopeptide is a cysteine-containing dipeptide. In certain embodiments, the cysteine-containing dipeptide is L(D)-cysteine-L(D)-arginine dipeptide (CR), L(D)-arginine-L(D)-cysteine dipeptide (RC), or L(D)-cysteine-L(D)-histidine dipeptide (CH). In certain embodiments, the cysteine-containing oligopeptide is a cysteine-containing tripeptide. In certain embodiments, the cysteine-containing tripeptide is glycine-L(D)-cysteine-L(D)-arginine tripeptide (GCR), L(D)-proline-L(D)-cysteine-L(D)-arginine tripeptide (PCR), or L-glutathione (GSH). In certain embodiments, the cysteine-containing oligopeptide is a cysteine-containing tetrapeptide, hi certain embodiments, the cysteine-containing tetrapeptide is glycine-L(D)-serine-L(D)-cysteine-L(D)-arginine tetrapeptide (GSCR) or glycine-L(D)-cysteine-L(D)-serine-L(D)-arginine tetrapeptide (GCSR).
[0047] In certain embodiments, the ligand is a thiol-containing compound, hi certain embodiments, the thiol-containing compound is 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-penicillamine, dodecyl mercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA), or 4-mercaptobenzoic acid (p-MBA).
[0048] The present invention provides pharmaceutical compositions for the treatment of subjects suffering from side effects due to atypical antipsychotics, including olanzapine, clozapine, risperidone, and quetiapine. In certain embodiments, the subject is a human. In certain embodiments, the subject is a pet animal, such as a dog.
[0049] In certain embodiments, the pharmaceutical composition comprises the ligand-bound AuC disclosed hereinabove and a pharmacologically acceptable excipient, in certain embodiments, the excipient is a phosphate buffer or saline.
[0050] The present invention provides the use of the ligand-conjugated AuCs disclosed hereinabove in the manufacture of a medicament for the treatment of a subject suffering from side effects due to atypical antipsychotics, including olanzapine, clozapine, risperidone, and quetiapine.
[0051] The present invention provides the use of the ligand-conjugated AuCs disclosed hereinabove for treating a subject suffering from side effects caused by atypical antipsychotics, including olanzapine, clozapine, risperidone, and quetiapine, or a method of treating a subject suffering from side effects caused by atypical antipsychotics, including olanzapine, clozapine, risperidone, and quetiapine, using the ligand-conjugated AuCs disclosed hereinabove. In certain embodiments, the method of treatment comprises administering to the subject a pharmacologic effective amount of the ligand-conjugated AuCs. The pharmacologic effective amount can be confirmed by routine in vivo studies.
[0052] In certain embodiments, the atypical antipsychotic and the ligand-conjugated AuCs can be co-administered. In certain embodiments, the atypical antipsychotic and the ligand-conjugated AuCs can be administered separately by the same or different routes.
[0053] The following examples are provided for the sole purpose of illustrating the principles of the present invention, and are not intended to limit the scope of the invention in any way.
[0054] Working Example
[0055] 1. Preparation of ligand-bound AuCs
[0056] 1.1 HAuCl4 was dissolved in methanol, water, ethanol, n-propanol, or ethyl acetate to obtain solution A with a HAuCl4 concentration of 0.01 to 0.03 M.
[0057] 1.2 The ligand was dissolved in a solvent to obtain solution B having a ligand concentration of 0.01 to 0.18 M. The ligands include L-cysteine, D-cysteine, and other cysteine derivatives such as N-isobutyryl-L-cysteine (L-NIBC), N-isobutyryl-D-cysteine (D-NIBC), N-acetyl-L-cysteine (L-NAC), and N-acetyl-D-cysteine (D-NAC), cysteine-containing oligopeptides and their derivatives (L(D)-cysteine-L(D)-arginine dipeptide (CR), L(D)-arginine-L(D)-cysteine dipeptide (RC), L(D)-cysteine Dipeptides, tripeptides and tetrapeptides such as L(D)-histidine (CH), glycine-L(D)-cysteine-L(D)-arginine tripeptide (GCR), L(D)-proline-L(D)-cysteine-L(D)-arginine tripeptide (PCR), L(D)-glutathione (GSH), glycine-L(D)-serine-L(D)-cysteine-L(D)-arginine tetrapeptide (GSCR) and glycine-L(D)-cysteine-L(D)-serine-L(D)-arginine tetrapeptide (GCSR). The solvents used in the present invention include, but are not limited to, thiol-containing compounds such as thiol, mercaptoethanol, thiophenol, D-penicillamine, dodecyl mercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA), and 4-mercaptobenzoic acid (p-MBA). The solvents were one or more of methanol, ethyl acetate, water, ethanol, n-propanol, pentane, formic acid, acetic acid, diethyl ether, acetone, anisole, 1-propanol, 2-propanol, 1-butanol, 2-butanol, pentanol, butyl acetate, t-butyl methyl ether, isopropyl acetate, dimethyl sulfoxide, ethyl formate, isobutyl acetate, methyl acetate, 2-methyl-1-propanol, and propyl acetate.
[0058] 1.3 Solution A and solution B were mixed so that the molar ratio of HAuCl4 to the ligand was 1: (0.01-100), and the mixture was stirred in an ice bath for 0.1-48 hours, and 0.025-0.8M NaBH4 in water, ethanol or methanol was added, and the mixture was stirred in an ice bath and reacted for 0.1-12 hours. The molar ratio of NaBH4 to the ligand was 1: (0.01-100).
[0059] 1.4 After the reaction was completed, the reaction solution was centrifuged for 10-100 minutes at a gradient of 8000-17500 r / min using an ultrafiltration tube with a MWCO of 3K-30K to obtain ligand-bound AuCs precipitates with different average particle sizes. The opening of the filtration membrane of the ultrafiltration tube with different MWCO directly determined the size of the ligand-bound AuCs that could pass through the membrane. This step may be omitted if desired.
[0060] 1.5 The ligand-bound AuCs precipitates with different average particle sizes obtained in step (1.4) were dissolved in water, loaded into a dialysis bag, and dialyzed in water at room temperature for 1-7 days.
[0061] 1.6 After dialysis, the ligand-bound AuCs was freeze-dried for 12 to 24 hours to obtain the ligand-bound AuCs as a powder or aggregated substance.
[0062] As can be seen from the measurements, the particle size of the powder or aggregated material obtained by the method was less than 3 nm (overall distributed in the range of 0.5-2.6 nm). There was no obvious absorption peak at 520 nm. It was identified that the obtained powder or aggregate was ligand-bound AuCs.
[0063] 2. Preparation and identification of AuCs with different ligands
[0064] 2.1 Preparation of L-NIBC-bound AuCs, i.e., L-NIBC-AuCs
[0065] Taking the ligand L-NIBC as an example, the preparation and confirmation of L-NIBC-bound AuCs will be described in detail below.
[0066] 2.1.1 1.00 g of HAuCl4 was weighed and dissolved in 100 mL of methanol to obtain a 0.03 M solution A.
[0067] 2.1.2 0.57 g of L-NIBC was weighed out and dissolved in 100 mL of glacial acetic acid (acetic acid) to obtain a 0.03 M solution B.
[0068] 2.1.3 1 mL of solution A was weighed out and mixed with 0.5 mL, 1 mL, 2 mL, 3 mL, 4 mL, or 5 mL of solution B, respectively (i.e., the molar ratios of HAuCl4 and L-NIBC were 1:0.5, 1:1, 1:2, 1:3, 1:4, and 1:5, respectively), and reacted in an ice bath with stirring for 2 hours. When the solution turned from light yellow to colorless, 1 mL of freshly prepared 0.03 M (prepared by weighing 11.3 mg of NaBH4 and dissolving it in 10 mL of ethanol) NaBH4 ethanol solution was promptly added. After the solution turned dark brown, the reaction was continued for 30 minutes, and 10 mL of acetone was added to quench the reaction.
[0069] 2.1.4 After the reaction, the reaction solution was subjected to gradient centrifugation to obtain L-NIBC-AuCs powders with different particle sizes. The specific method is as follows: After the reaction is completed, the reaction solution was transferred to an ultrafiltration tube with a MWCO of 30K and a volume of 50mL, and centrifuged at 10,000r / min for 20 minutes, and the retentate in the inner tube was dissolved in ultrapure water to obtain a powder with a particle size of about 2.6nm. Then, the mixture in the outer tube was transferred to an ultrafiltration tube with a volume of 50mL and a MWCO of 10K, and centrifuged at 13,000r / min for 30 minutes. The retentate in the inner tube was dissolved in ultrapure water to obtain a powder with a particle size of about 1.8nm. Then, the mixture in the outer tube was transferred to an ultrafiltration tube with a volume of 50mL and a MWCO of 3K, and centrifuged at 17,500r / min for 40 minutes. The retentate in the inner tube was dissolved in ultrapure water to obtain a powder with a particle size of approximately 1.1 nm.
[0070] 2.1.5 The powders with three different particle sizes obtained by gradient centrifugation were precipitated, the solvent was removed respectively, the crude products were blown dry with N2, dissolved in 5mL of ultrapure water, placed in a dialysis bag (MWCO 3KDa), the dialysis bag was placed in 2L of ultrapure water, the water was changed every other day, dialyzed for 7 days, freeze-dried, and kept for future use.
[0071] 2.2 Identification of L-NIBC-AuCs
[0072] The identification experiment was carried out on the powder (L-NIBC-AuC) obtained above. At the same time, gold nanoparticles modified with the ligand L-NIBC (L-NIBC-AuNPs) were used as a control. The preparation method of gold nanoparticles with the ligand L-NIBC is referred to references (W. Yan, L. Xu, C. Xu, W. Ma, H. Kuang, L. Wang and NAKotov, Journal of American Chemical Society 2012, 134, 15114; X. Yuan, B. Zhang, Z. Luo, Q. Yao, DT Leong, N. Yan and J. Xie, Angewandte Chemie International Edition 2014, 53, 4623).
[0073] 2.2.1 Morphology observation using a transmission electron microscope (TEM)
[0074] The test powders (L-NIBC-AuCs sample and L-NIBC-AuNPs sample) were dissolved in ultrapure water to 2 mg / L to prepare the test samples, and the test samples were prepared by the hanging drop method. More specifically, 5 μL of the sample was dropped onto an ultrathin carbon film, and the film was allowed to evaporate naturally until there were no water droplets, and the morphology of the sample was observed by a JEM-2100F STEM / EDS field emission high-resolution TEM.
[0075] Four TEM images of L-NIBC-AuNPs are shown in panels B, E, H, and K of Figure 1, and three TEM images of L-NIBC-AuCs are shown in panels B, E, and H of Figure 2.
[0076] As shown in the images in Figure 2, each L-NIBC-AuCs sample had uniform particle size and good dispersibility, and the average diameters of L-NIBC-AuCs (referred to as the diameter of the gold core) were 1.1 nm, 1.8 nm, and 2.6 nm, respectively, which were in good agreement with the results in panels C, F, and I of Figure 2. In contrast, the L-NIBC-AuNPs sample had larger particle sizes. Their average diameters (referred to as the diameter of the gold core) were 3.6 nm, 6.0 nm, 10.1 nm, and 18.2 nm, respectively, which were in good agreement with the results in panels C, F, I, and L of Figure 1.
[0077] 2.2.2 Ultraviolet (UV)-visible (vis) absorption spectrum
[0078] The test powders (L-NIBC-AuCs sample and L-NIBC-AuNPs sample) were dissolved in ultrapure water to a concentration of 10 mg L -1 The UV-vis absorption spectrum was measured at room temperature. The scanning range was 190-1100 nm, the sample cell was a standard quartz cuvette with a path length of 1 cm, and the reference cell was filled with ultrapure water.
[0079] The UV-vis absorption spectra of four L-NIBC-AuNPs samples with different sizes are shown in panels A, D, G, and J of FIG. 1, and the statistical distribution of particle sizes is shown in panels C, F, I, and L of FIG. 1. The UV-vis absorption spectra of three L-NIBC-AuCs samples with different sizes are shown in panels A, D, and G of FIG. 2, and the statistical distribution of particle sizes is shown in panels C, F, and I of FIG. 2.
[0080] As shown in FIG. 1, due to the surface plasmon effect, L-NIBC-AuNPs had an absorption peak at about 520 nm. The position of the absorption peak was related to the particle size. When the particle size was 3.6 nm, the UV absorption peak appeared at 516 nm, when the particle size was 6.0 nm, the UV absorption peak appeared at 517 nm, when the particle size was 10.1 nm, the UV absorption peak appeared at 520 nm, and when the particle size was 18.2 nm, the absorption peak appeared at 523 nm. None of the four samples had an absorption peak above 560 nm.
[0081] As shown in Figure 2, the UV absorption spectra of L-NIBC-AuCs samples with different particle sizes showed the disappearance of the absorption peak due to the surface plasmon effect at 520 nm, and two obvious absorption peaks appeared above 560 nm, with slight differences in the positions of the absorption peaks depending on the particle size of AuCs. This is because AuCs exhibited molecular-like properties due to the collapse of the face-centered cubic structure, leading to discontinuity of the density of states of AuCs, splitting of the energy levels, disappearance of the plasmon resonance effect, and a new absorption peak in the long-wave direction. It can be concluded that all three powder samples with different particle sizes obtained above were ligand-bound AuCs.
[0082] 2.2.3 Fourier transform infrared spectroscopy
[0083] Infrared spectra were measured on a Bruker VERTEX80V Fourier transform infrared spectrometer in solid powder high vacuum total reflection mode. The scan range was 4000–400 cm. -1 The number of scans was 64. Taking the L-NIBC-AuCs sample as an example, the test samples were L-NIBC-AuCs dry powders with three different particle sizes, and the control sample was pure L-NIBC powder. The results are shown in Figure 3.
[0084] Figure 3 shows the infrared spectra of L-NIBC-AuCs with different particle sizes. Compared with pure L-NIBC (lower curve), the SH stretching vibrations of L-NIBC-AuCs with different particle sizes are all located in the range of 2500 to 2600 cm -1 The infrared spectrum of the ligand-bound AuCs was completely disappeared at 37°C, whereas the other characteristic peaks of L-NIBC still remained, proving that the L-NIBC molecules were successfully immobilized on the surface of AuCs via Au-S bonds. This figure also showed that the infrared spectrum of the ligand-bound AuCs was independent of their size.
[0085] AuCs bound with other ligands were prepared in the same manner as above, except that the solvent of solution B, the ratio of HAuCl4 to ligand, reaction time, and the amount of NaBH4 added were slightly adjusted. Other steps were also performed in the same manner, for example, when L-cysteine, D-cysteine, N-isobutyryl-L-cysteine (L-NIBC) or N-isobutyryl-D-cysteine (D-NIBC) was used as the ligand, acetic acid was selected as the solvent, and when dipeptide CR, dipeptide RC or 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline was used as the ligand, water was selected as the solvent, and further details are omitted here.
[0086] The present invention prepared a series of ligand-conjugated AuCs by the above-mentioned method. The ligands and preparation process parameters are shown in Table 1.
[0087] Table 1. Preparation parameters of AuCs with different ligands in the present invention. JPEG0007595087000003.jpg223164
[0088] The samples listed in Table 1 were confirmed by the above method. The properties of nine different ligand-conjugated AuCs are shown in Figure 4 (CR-AuCs), Figure 5 (RC-AuCs), Figure 6 (Cap-AuCs) (Cap is 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline), Figure 7 (GSH-AuCs), Figure 8 (D-NIBC-AuCs), Figure 9 (L-Cys-AuCs), Figure 10 (CSH-AuCs), Figure 11 (MPA-AuCs), and Figure 12 (p-MBA-AuCs). Figures 4-12 show the UV spectrum (panel A), infrared spectrum (panel B), TEM image (panel C), and particle size distribution (panel D).
[0089] As a result, the diameters of the AuCs bound to different ligands obtained from Table 1 were all less than 3 nm. The ultraviolet spectrum also showed the disappearance of a peak at 520±20 nm and the appearance of an absorption peak at another position. The position of this absorption peak differed depending on the ligand, particle size, and structure. In certain situations, a special absorption peak was not formed, mainly because a mixture of AuCs with different particle sizes and structures was formed, or the position of the absorption peak was moved outside the range of the ultraviolet-visible spectrum by a certain special AuCs. On the other hand, in the Fourier transform infrared spectrum, the infrared absorption peak of the thiol of the ligand (between the dotted lines in Panel B of Figures 4 to 8) disappeared, but all other infrared characteristic peaks were retained, indicating that all the ligand molecules were successfully fixed on the surface of AuCs, and the present invention was successful in obtaining AuCs bound to the ligands listed in Table 1.
[0090] 3. Animal testing
[0091] 3.1 Test sample
[0092] A1: Ligand L-NIBC-conjugated gold clusters (L-NIBC-AuCs), with a size distribution of 0.5–3 nm.
[0093] A2: Ligand N-acetyl-L-cysteine-conjugated gold clusters (L-NAC-AuCs), with a size distribution of 0.5–3 nm.
[0094] A3: Ligand L-cysteine-conjugated gold clusters (L-Cys-AuCs), with a size distribution of 0.5–3 nm.
[0095] A4: Ligand 2-aminoethanethiol-conjugated gold clusters (CSH-AuCs), with a size distribution of 0.5–3 nm.
[0096] A5: Ligand 3-mercaptopropionic acid-conjugated gold clusters (MPA-AuCs), with a size distribution of 0.5–3 nm.
[0097] A6: Ligand 4-mercaptobenzoic acid-bound gold clusters (p-MBA-AuCs), with a size distribution of 0.5–3 nm.
[0098] B: L-NIBC-conjugated gold nanoparticles (L-NIBC-AuNPs), with a size distribution of 5–9 nm.
[0099] All test samples were prepared according to the method described above with minor modifications, and their quality was characterized using the method described above.
[0100] 3.2 Establishment of an olanzapine-induced side effect model and investigation of the inhibitory effects and dose-effects of different ligand-bound AuCs on olanzapine-induced weight gain
[0101] One hundred and forty-four SPF female Sprague Dawley rats (8-10 weeks old) were purchased from the Experimental Animal Center of SiPeifu (Beijing) Biotechnology Co., Ltd. All rats were raised in an isolated environment, the temperature was controlled at 22 ± 2°C, and the day-night interval was 12 h, with 7:00 to 19:00 as day and 19:00 to 7:00 as night. After 1 week of adaptation feeding, the rats were randomly divided into 12 groups (n = 12 / group, ensuring that the average body weight and food intake of each group of rats were similar): negative control group (CON, group 1), olanzapine model control group (OLZ, group 2), olanzapine + A1 high dose group (OLZ + A1H, group 3), olanzapine + A1 low dose group (OLZ + A1L, group 4), olanzapine + A2 high dose group (OLZ + A2H, group 5), and olanzapine + A2 low dose group (OLZ + A2H, group 6). The lanzapine + A2 low-dose group (OLZ+A2L, group 6), olanzapine + A3 high-dose group (OLZ+A3H, group 7), olanzapine + A3 low-dose group (OLZ+A3L, group 8), olanzapine + A4 high-dose group (OLZ+A4H, group 9), olanzapine + A5 high-dose group (OLZ+A5H, group 10), olanzapine + A6 high-dose group (OLZ+A6H, group 11), and olanzapine + B high-dose group (OLZ+B, group 12). Rats in groups 2-12 were orally administered olanzapine (1 mg / kg, tid (three times a day), at dosing times: 07:00, 15:00, and 23:00), and the negative control group (group 1) was administered an equal amount of placebo as a control, where olanzapine was orally administered to rats in pellets made of 0.3 g of diet (mixed with 24.3% casein, 34.3% cornstarch, 34.36% sucrose, and 6.98% gelatin). The placebo was a food pill containing the same amount of olanzapine. Starting from the first day of olanzapine (or placebo) administration, the olanzapine + high-dose drug group was intraperitoneally injected with drugs A1, A2, A3, A4, A5, A6 or B (20 mg / kg, once daily), and the olanzapine + low-dose drug group was intraperitoneally injected with drugs A1, A2 or A3 (10 mg / kg, once daily). The negative control group and the olanzapine model control group were intraperitoneally injected with the same amount of saline as a control. The same administration method was performed for 21 consecutive days.Food intake of animals was measured every 24 h, and animal body weight was measured every 48 h to observe the inhibitory effect of different doses of AuCs on olanzapine-induced weight gain.
[0102] 3.3 Glucose tolerance test
[0103] On the 21st day of administration, all rats were fasted for 16 h. Blood samples were collected from the tail vein of the rats, and the fasting blood glucose levels (0 h) of the rats were measured by a blood glucose meter (Johnson & Johnson One Touch Ultra, Johnson & Johnson (China) Medical Equipment Co., Ltd) after intraperitoneal injection of the corresponding dose of glucose solution (1 g / kg), and the blood glucose levels were measured at 30 min, 60 min, 90 min, and 120 min after administration of the glucose solution, and the area under the curve (AUC) of each mouse was calculated.
[0104] 3.4 Euthanasia of rats and tissue collection
[0105] After the last dose, rats were anesthetized with 7% chloral hydrate. After cardiac blood samples were taken, liver, mesenteric, perirenal, and periovarian tissues were harvested, weighed, and stored at -80°C.
[0106] 3.5 Data Statistics and Analysis
[0107] Statistical analysis was performed on all data using SPSS 22.0 statistical software. All data are expressed as mean ± SEM, and statistical differences are defined as P < 0.05.
[0108] 3.6 Experimental results
[0109] 3.6.1 Administration of gold cluster drugs significantly reduced olanzapine-induced weight gain and food intake in rats.
[0110] Table 2 shows the weight changes of rats in the negative control group, the olanzapine model control group, the high- and low-dose groups of the three AuCs (A1, A2, and A3), and the AuNPs high-dose group. As shown in Table 2, the initial body weights (IBW) of all groups of rats were almost the same (245.48g-247.86g). After 21 days of drug administration, the final body weight (FBW) of the olanzapine model control group was significantly higher than that of the negative control group (P<0.01), indicating that the model was successfully established. Compared with the olanzapine model control group, the weights of the high-dose gold cluster drug groups (OLZ+A1H, OLZ+A2H, and OLZ+A3H) were significantly lower (both P<0.05), and those of the low-dose gold cluster drug groups (OLZ+A1L, OLZ+A2L, and OLZ+A3L) were obviously lower. At the same time, compared with the negative control group, the final weight gain (BWG, i.e., the difference between final weight and initial weight) of the olanzapine model control group was highly significantly increased (P<0.01). Compared with the olanzapine model control group, the final weight gain (BGW) of the high-dose gold cluster drug groups (OLZ+A1H, OLZ+A2H, and OLZ+A3H) was highly significantly decreased (both P<0.01). The final weight gain (BGW) of the low-dose gold cluster drug groups (OLZ+A1L, OLZ+A2L, and OLZ+A3L) was also significantly decreased (both P<0.05). The other three high-dose gold cluster drug groups (OLZ+A4H, OLZ+A5H, and OLZ+A6H) showed similar results. However, compared with the olanzapine model control group, the final body weight (FBW) and final body weight gain (BGW) of the high-dose gold nanoparticle drug group (OLZ+B) were not significantly decreased (P>0.05).
[0111] Table 2: Effect of various drug administrations on olanzapine-induced weight gain in rats. JPEG0007595087000004.jpg12598
[0112] In Table 2, IBW: initial body weight; FBW: final body weight; BWG: body weight gain; CON: negative control group; OLZ: olanzapine model control group; OLZ+A1H: OLZ+A1 high dose group; OLZ+A1L: OLZ+A1 low dose group; OLZ+A2H: OLZ+A2 high dose group; OLZ+A2L: OLZ+A2 low dose group; OLZ+A3H: OLZ+A3 high dose group; OLZ+A3L: OLZ+A3 low dose group; OLZ+B: OLZ+B high dose group; *: P<0.05, OLZ vs. CON; **: P<0.01, OLZ vs. CON; #: P<0.05, each treatment group vs. OLZ; ##: P<0.01, each treatment group vs. OLZ.
[0113] 3.6.2 Administration of gold cluster drugs significantly reduced the increase in mesenteric fat caused by olanzapine.
[0114] Olanzapine-induced weight gain may lead to fatty liver. Table 3 shows the changes in liver weight and mesenteric fat of rats in the negative control group, the olanzapine model control group, the high- and low-dose groups of three AuCs (A1, A2, and A3), and the AuNPs high-dose group. As shown in Table 3, compared with the negative control group, the liver weight increased in the olanzapine model control group, but there was no significant difference (P>0.05). Compared with the olanzapine model control group, the three different dose groups of gold cluster drugs could reduce liver weight, and the low-dose group of A1 and the high-dose group of A3 showed significant differences (P<0.05). In peripheral fat, compared with the negative control group, the olanzapine model control group significantly increased the accumulation of intestinal fat (P<0.05). Compared with the olanzapine model control group, both high and low doses of A1, A2, and A3 reduced the increase in peri-intestinal fat induced by olanzapine in a dose-dependent manner (the maximum weight loss rate was as high as 32%). The other three high-dose gold cluster drug groups (OLZ+A4H, OLZ+A5H, and OLZ+A6H) showed similar results. In summary, the gold cluster drug can obviously reduce the increase in fat caused by olanzapine, showing a certain dose-dependency. However, the high-dose group of gold nanoparticles showed no significant change, indicating that gold nanoparticles are ineffective.
[0115] Table 3: Effects of drugs on rat liver and perintestinal fat weights JPEG0007595087000005.jpg7095
[0116] In Table 3, CON: negative control group; OLZ: olanzapine model control group; OLZ+A1H: OLZ+A1 high dose group; OLZ+A1L: OLZ+A1 low dose group; OLZ+A2H: OLZ+A2 high dose group; OLZ+A2L: OLZ+A2 low dose group; OLZ+A3H: OLZ+A3 high dose group; OLZ+A3L: OLZ+A3 low dose group; OLZ+B: OLZ+B high dose group; *: P<0.05, OLZ vs. CON; #: P<0.05, each treatment group vs. OLZ; ♯♯: P<0.01, each treatment group vs. OLZ.
[0117] 3.6.3 Administration of gold cluster drugs significantly suppressed the rise in blood glucose caused by olanzapine.
[0118] Clinically, administration of olanzapine can cause elevated blood glucose levels and diabetes. Figure 13 shows the blood glucose metabolic curves and area under the blood glucose curve (AUG) of rats in the negative control group, the olanzapine model control group, the high- and low-dose groups of three AuCs (A1, A2, and A3), and the AuNP high-dose group.
[0119] In this study, we found that the control group and various administration groups of the olanzapine model had no significant effect on fasting blood glucose (P>0.05). However, compared with the negative control group, after glucose injection, the blood glucose levels of the olanzapine model control group rats increased significantly at 30 min (P<0.01) and 120 min (P<0.05) after intraperitoneal glucose injection, from 7.54±0.26mmol / L and 6.11±0.12mmol / L to 9.16±0.48mmol / L and 6.79±0.32mmol / L, respectively (Figure 13A). The area under the blood glucose curve (AUG) increased significantly from 766.83±15.05mmol / min to 845.07±37.88mmol / min (P<0.05, Figure 13B). The above results indicate a significant effect of olanzapine administration on glucose metabolism disorders in animals.
[0120] Compared with the olanzapine model control group, the blood glucose levels of the three gold cluster drug (A1, A2, and A3) groups were significantly decreased, especially in the high-dose group. The blood glucose levels of the three rats in the high-dose group were significantly decreased at 30 minutes (both P<0.01), 60 minutes (both P<0.01), and 120 minutes (both P<0.01) after glucose injection, and the blood glucose levels were close to that of the negative control group (Figure 13A). Taking A1 as an example, the blood glucose levels at these three time points were decreased from 9.16±0.48mmol / L, 6.79±0.32mmol / L, and 6.30±0.33mmol / L in the olanzapine model control group to 7.7±0.15mmol / L, 5.74±0.18mmol / L, and 5.53±0.14mmol / L, respectively (Figure 13A). In addition, the areas under the blood glucose curve (AUG) of the three high-dose gold cluster drugs were also significantly lower than that of the olanzapine model control group (both P<0.01, Figure 13B). Taking A1 (OLZ+A1H) as an example, the AUG value decreased from 845.07±37.88mmol / min in the olanzapine model control group (OLZ) to 743.50±13.04mmol / min. The blood glucose levels of the three rats with low-dose gold cluster drugs also decreased obviously at different time points, but both showed significant differences only at 30 min (P<0.05). The other three high-dose gold cluster drug groups (OLZ+A4H, OLZ+A5H, and OLZ+A6H) showed similar results. This indicates that gold cluster drugs can improve blood glucose metabolism disorders caused by olanzapine in a dose-dependent manner.
[0121] However, administration of gold nanoparticles (B) did not significantly reduce blood glucose concentration (FIG. 13A) or area under the blood glucose curve (AUG) (FIG. 13B) at different periods. Therefore, there was no ameliorative effect on blood glucose metabolism disorders caused by olanzapine.
[0122] In summary, long-term administration of gold clusters can significantly reduce weight gain and fat gain caused by olanzapine and significantly improve lipid and glucose metabolic disorders caused by olanzapine, providing a basis for the next research and development of gold clusters as a medicine to reduce the side effects of second-generation antipsychotics. However, gold nanoparticles do not have such effects and cannot be used as a treatment for olanzapine-induced obesity.
[0123] Other ligand-conjugated AuCs of different sizes, such as L-Cys-AuCs, L-NAC-AuCs, L-NIBC-AuCs, CSH-AuCs, MPA-AuCs, and p-MBA-AuCs, also have effects on the suppression of EAE, and their effects vary to some extent, which will not be described in detail here.
[0124] Although the present invention has been described with reference to specific embodiments, it is understood that these embodiments are illustrative and that the scope of the invention is not so limited. Alternative embodiments of the invention will be apparent to those skilled in the art to which the invention pertains. Such alternative embodiments are considered to be encompassed within the scope of the invention. The scope of the invention is therefore defined by the appended claims and supported by the foregoing description.
Claims
1. 1. A pharmaceutical composition for treating side effects caused by an atypical antipsychotic, said pharmaceutical composition comprising a ligand-conjugated gold cluster, said ligand-conjugated gold cluster comprising: Gold core and a ligand bound to said gold core; Including, the diameter of the gold core is between 0.5 and 3 nm; the ligand is one selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds; The L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC), and N-acetyl-L-cysteine (L-NAC), and the D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC), and N-acetyl-D-cysteine (D-NAC), The cysteine-containing oligopeptide and its derivatives are a cysteine-containing dipeptide, a cysteine-containing tripeptide or a cysteine-containing tetrapeptide; The other thiol-containing compound is selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-penicillamine, N-(2-mercaptopropionyl)-glycine, dodecyl mercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA), and 4-mercaptobenzoic acid (p-MBA); Pharmaceutical compositions.
2. 2. The pharmaceutical composition of claim 1, wherein the gold core has a diameter of 0.5 to 2.6 nm.
3. 2. The pharmaceutical composition of claim 1, wherein the cysteine-containing dipeptide is selected from the group consisting of L(D)-cysteine-L(D)-arginine dipeptide (CR), L(D)-arginine-L(D)-cysteine dipeptide (RC), L(D)-histidine-L(D)-cysteine dipeptide (HC), and L(D)-cysteine-L(D)-histidine dipeptide (CH).
4. 2. The pharmaceutical composition of claim 1, wherein the cysteine-containing tripeptide is selected from the group consisting of glycine-L(D)-cysteine-L(D)-arginine tripeptide (GCR), L(D)-proline-L(D)-cysteine-L(D)-arginine tripeptide (PCR), L(D)-lysine-L(D)-cysteine-L(D)-proline tripeptide (KCP), and L(D)-glutathione (GSH).
5. 2. The pharmaceutical composition of claim 1, wherein the cysteine-containing tetrapeptide is selected from the group consisting of glycine-L(D)-serine-L(D)-cysteine-L(D)-arginine tetrapeptide (GSCR) and glycine-L(D)-cysteine-L(D)-serine-L(D)-arginine tetrapeptide (GCSR).
6. 2. The pharmaceutical composition of claim 1, wherein the atypical antipsychotic is one selected from the group consisting of olanzapine, clozapine, risperidone, and quetiapine.
Citation Information
Patent Citations
Combination therapy
JP2010507572A
Methods and compositions for treating psychotic disorders
JP2017534673A
Therapeutic uses of atomic quantum clusters
JP2022502450A
